Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: May 27, 2026
Reporting Period: Single event date (May 27, 2026)
Business Context: The registrant is a Delaware corporation listed on the Nasdaq Capital Market. It is classified as an emerging growth company.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Intellectual Property Milestone: On May 27, 2026, the company received notification of allowance from the Mexican Institute of Industrial Property for a patent application. The patent relates to methods of predicting the likelihood of lung cancer using flow cytometry.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the patent allowance but does not provide forward-looking guidance, financial outlook, or specific risk factors within the body of this report.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the scope and enforceability of the newly allowed Mexican patent regarding lung cancer prediction methods.
- Review the full text of the press release attached as Exhibit 99.1 for additional details on commercialization plans.
- Confirm the company's status as an emerging growth company and any associated reporting exemptions.
- Check subsequent filings for financial impact or revenue recognition related to this intellectual property.